Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 20 August 2024 -- This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Sylvie Louise Grégoire | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, |
ADRs |
||||
| Identification code | NVO | |||||
| b) | Nature of the transaction | Purchase of ADRs | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 913.15 | 2 ADRs | |||||
| DKK 913.05 | 200 ADRs | |||||
| DKK 912.75 | 1 ADRs | |||||
| DKK 912.68 | 431 ADRs | |||||
| DKK 912.61 | 232 ADRs | |||||
| DKK 912.55 | 379 ADRs | |||||
| DKK 912.34 | 255 ADRs | |||||
| d) | Aggregated information Aggregated volumePrice | 1,500 ADRs DKK 1,368,944.39 |
||||
| e) | Date of the transaction | 2024-08-19 | ||||
| f) | Place of the transaction | New York Stock Exchange | ||||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com |
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement no 65 / 2024
Attachment
\Hugin
Mest læste lige nu
Seneste nyheder
- 1 af 1181
- næste ›